Valproic Acid Use in Patients With Neurological Disorders

Status Completed

Clinical Trial Summary

Sodium valproate is a well-known anticonvulsant used in the treatment of epilepsy and bipolar disorder, as well as other psychiatric conditions requiring the administration of mood stabilizers. Aim of the present study is to assess sodium valproate usage among patients with neurological disorders. Prescriptions of 600 patients from out-patient pharmacy of neurology department at Mansoura university teaching hospital were analyzed in a retrospective prospective observational study which conducted between January 2015 and December 2017. Data collected include: demographic data, medical history, drug-drug interaction, polypharmacy, medication error, doses and therapeutic duplication. A designed and structured form was used to collect the required information.

Clinical Trial Description

This retrospective prospective observational study was conducted at the outpatient's pharmacy of Neurology department at tertiary care hospital. After identifying problems with use and completing a follow-up, 3 months of educational intervention (Lectures) among professionals was given. As this study is observational informed consent from all subjects was waived. The subjects were enrolled on the basis of inclusion and exclusion criteria. Patients receiving at least 7 days of Valproic acid, between 10-70 years old, both sexes, were included in the study figure 1. 600 Prescriptions were reviewed between January of 2015 to December of 2017 for patients who were suffering from any psychotic illness and were on psychiatric medications. Then pharmacist educational intervention started and followed up for three months then prescriptions re-evaluted. Inclusion/ exclusion criteria: The study population was limited to those who were continuously eligible for the outpatient pharmacy refilling thier medications during the entire study period. Patients were identified through pharmacy drug prescriptions By hospital policy all drugs are prescribed for a maximum period of 3 months. Consequently, all patients presented at least twice during the study period. A designed and structured form was used to collect the required information. Data then collected on Microsoft Excel sheet, which included patients' initial therapeutic indications, concomitant use of oral medications, significant adverse drug effects and any drug -drug interaction. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05830981
Study type	Observational
Source	Damanhour University
Contact
Status	Completed
Phase
Start date	January 1, 2015
Completion date	December 31, 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01589289` - Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases in Neurological Disorders in DRC	Phase 3
Completed	`NCT00010881` - Oregon Center for Complementary and Alternative Medicine in Neurological Disorders	N/A
Recruiting	`NCT04461821` - Exhaled Breath Analysis by Secondary Electrospray Ionization - Mass Spectrometry in Children and Adolescents
Completed	`NCT04094571` - Muscle Delay Characterization	N/A
Completed	`NCT04072536` - Evaluation on Standardized Circuits of the Interest of a Robotic Module of Assistance to the Driving	N/A
Recruiting	`NCT02795052` - Neurologic Stem Cell Treatment Study	N/A
Completed	`NCT02219269` - A Complex Contraception Registry	N/A
Completed	`NCT00122174` - Stress-Busting Program for Caregivers of Patients With Neruological Diseases	N/A
Recruiting	`NCT01524276` - Product Surveillance Registry
Completed	`NCT00532571` - Effects of Coenzyme Q10 in PSP and CBD	Phase 2/Phase 3
Completed	`NCT01754168` - Amyloid Beta and Cognition in Parkinson Disease	N/A
Completed	`NCT02780531` - Genetic and Blood Biomarkers in Neurological and Neuromuscular Diseases
Completed	`NCT01858350` - Comparison of the Effectiveness of CAM Therapies in Pediatric Patients Undergoing Sedation	N/A
Suspended	`NCT05212727` - Development and Validation of a Novel Functional Eye-Tracking Software Application for Neurological Disorders
Recruiting	`NCT01266382` - The Effect of AposTherapy on the Level of Pain, Function and Quality of Life in Patients With Neuro-muscular and Neurological Disorders	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.